Production and post-surgical modification of VEGF, tPA and PAI-1 in patients with glioma

Cancer Biology and Therapy

Volumn 5, Issue 2, 2006, Pages 204-209

  Salmaggi, Andrea ^a   Croci, Danilo ^a   Prina, Paola ^a   Cajola, Laura ^a   Pollo, Bianca ^a   Marras, Carlo E ^a   Ciusani, Emilio ^a   Silvani, Antonio ^a   Boiardi, Amerigo ^a   Sciacca, Francesca L ^a  

^a DEPARTMENT OF NEUROSURGERY   (Italy)

Author keywords

High grade glioma; lp (a); PAI 1; Thromboembolism; tPA; VEGF

Indexed keywords

LIPOPROTEIN A; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR; VASCULOTROPIN;

ADULT; ARTICLE; BLOOD; BLOOD CELL; BLOOD VESSEL; CANCER PATIENT; CANCER SURGERY; CLINICAL ARTICLE; CONTROLLED STUDY; EXTRACELLULAR MATRIX; FEMALE; GLIOMA; GLIOMA CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; PERIPHERAL CIRCULATION; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN SECRETION; TUMOR CELL;

EID: 33644639262     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.5.2.2357     Document Type: Article

References (30)

1. Otten HM, Prins MH. Venous thromboembolism and occult malignancy. Thromb Res 2001; 102:V187-94.
2. Marras LC, Geerts WH, Perry JR. The risk of venous thromboembolism is increased throughout the course of malignant glioma: An evidence-based review. Cancer 2000; 89:640-6.
3. Flordal PA, Bergqvist D, Ljungstrom KG, Torngren S. Clinical relevance of the fibrinogen uptake test in patients undergoing elective general abdominal surgery - relation to major thromboembolism and mortality. Fragmin Multicentre Study Group. Thromb Res 1995; 80:491-7.
4. Brandes AA, Scelzi E, Salmistraro G, Ermani M, Carollo C, Berti F, et al. Incidence of risk of thromboembolism during treatment high-grade gliomas: A prospective study. Eur J Cancer 1997;33:1592-6.
5. Silvani A, Salmaggi A, Eoli M, Lamperti E, Boiardi A. Venous thromboembolism in malignant glioma patients treated by chemoradiotherapy. Neurol Sci 2003; 24:272.
6. Sciacca FL, Ciusani E, Silvani A, Corsini E, Frigerio S, Pogliani S, et al. Genetic and plasma markers of venous thromboembolism in patients with high grade glioma. Clin Cancer Res 2004; 10:312-7.
7. Guan M, Jin J, Su B, Liu WW, Lu Y. Tissue factor expression and angiogenesis in human glioma. Clin Biochem 2002; 35:321-5.
8. Takano S, Tsuboi K, Tomono Y, Mitsui Y, Nose T. Tissue factor, osteopontin, alphavbeta3 integrin expression in microvasculature of gliomas associated with vascular endothelial growth factor expression. Br J Cancer 2000; 82:1967-73.
9. Hjortland GO, Lillehammer T, Somme S, Wang J, Halvorsen T, Juell S, Hirschberg H, Fodstad O, Engebraaten O. Plasminogen activator inhibitor-1 increases the expression of VEGF in human glioma cells. Exp Cell Res 2004; 294:130-9.
10. Rodas RA, Fenstermaker RA, McKeever PE, Blaivas M, Dickinson LD, Papadopoulos SM, et al. Correlation of intraluminal thrombosis in brain tumor vessels with postoperative thrombotic complications: A preliminary report. J Neurosurg 1998; 89:200-5.
11. Peraud A, Mondal S, Hawkins C, Mastronardi M, Bailey K, Rutka JT. Expression of fascin, an actin-bundling protein, in astrocytomas of varying grades. Brain Tumor Pathol 2003; 20:53-8.
12. Ruff RL, Posner JB. Incidence and treatment of peripheral venous thrombosis in patients with glioma. Ann Neurol 1983; 13:334-6.
13. Sawaya R, Zuccarello M, Elkalliny M, Nishiyama H. Postoperative venous thromboembolism and brain tumors: Part I. Clinical profile. J Neurooncol 1992; 14:119-25.
14. Dhami MS, Bona RD, Calogero JA, Hellman RM. Venous thromboembolism and high grade gliomas. Thromb Haemost 1993; 70:393-6.
15. Zhou YH, Tan F, Hess KR, Yung WK. The expression of PAX6, PTEN, vascular endothelial growth factor, and epidermal growth factor receptor in gliomas: Relationship to tumor grade and survival. Clin Cancer Res 2003; 9:3369-75.
16. Johansson M, Brannstrom T, Bergenheim AT, Henriksson R. Spatial expression of VEGF-A in human glioma. J Neurooncol 2002; 59:1-6.
17. Nagashima G, Suzuki R, Asai J, Fujimoto T. Immunohistochemical analysis of reactive astrocytes around glioblastoma: An immunohistochemical study of postmortem glioblastoma cases. Clin Neurol Neurosurg 2002; 104:125-31.
18. Sawaya R, Highsmith R. Hyalinizing plasmacytic granulomatosis of the falx. Am J Surg Pathol 1988; 12:308-13.
19. Sawaya R, Ramo OJ, Glas-Greenwalt P, Wu SZ. Plasma fibrinolytic profile in patients with brain tumors. Thromb Haemost 1991; 65:15-9.
20. Kinder DH, Berger MS, Mueller BA, Silber JR. Urokinase plasminogen activator is elevated in human astrocytic gliomas relative to normal adjacent brain. Oncol Res 1993; 5:409-14.
21. Landau BJ, Kwaan HC, Verrusio EN, Brem SS. Elevated levels of urokinase-type plasminogen activator and plasminogen activator inhibitor type-1 in malignant human brain tumors. Cancer Res 1994; 54:1105-8.
22. Bindal AK, Hammoud M, Shi WM, Wu SZ, Sawaya R, Rao JS. Prognostic significance of prateolytic enzymes in human brain tumors. J Neurooncol 1994; 22:101-10.
23. Kono S, Rao JS, Bruner JM, Sawaya R. Immunohistochemical localization of plasminogen activator inhibitor type 1 in human brain tumors. J Neuropathol Exp Neurol 1994; 53:256-62.
24. Arai Y, Kubota T, Nakagawa T, Kabuto M, Sato K, Kobayashi H. Production of urokinase-type plasminogen activator (u-PA) and plasminogen activator inhibitor-1 (PAI-1) in human brain tumours. Acta Neurochir (Wien) 1998; 140:377-86.
25. Dietzmann K, von Bossanyi P, Krause D, Wittig H, Mawrin C, Kirches E. Expression of the plasminogen activator system and the inhibitors PAI-1 and PAI-2 in posttraumatic lesions of the CNS and brain injuries following dramatic circulatory arrests: An immunohistochemical study. Pathol Res Pract 2000; 196:15-21.
26. Lacroix M, Abi-Said D, Fourney DR, Gokaslan ZL, Shi W, DeMonte F, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: Prognosis, extent of resection, and survival. J Neurosurg 2001; 95:190-8.
27. DeClerck YA, Mercurio AM, Stack MS, Chapman HA, Zutter MM, Muschel RJ, et al. Proteases, extracellular matrix, and cancer: A workshop of the path B study section. Am J Pathol 2004; 164:1131-9.
28. Noel A, Maillard C, Rocks N, Jost M, Chabottaux V, Sounni NE, et al. Membrane associated proteases and their inhibitors in tumour angiogenesis. J Clin Pathol 2004; 57:577-84.
29. Goldhaber SZ, Dunn K, Gerhard-Herman M, Park JK, Black PM. Low rate of venous thromboembolism after craniotomy for brain tumor using multimodality profilaxis. Chest 2002; 122:1933-7.
30. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004; 3:391-400.